Authors
Latest:
Locoregional Liver-Directed Therapies to Treat Unresectable Colorectal Liver Metastases: A ReviewThis review article written by Nikia R. McFadden, MD, MAS, et al, discusses which therapies are best to treat unresectable colorectal liver metastases.
Latest:
Unmet Needs and Key Takeaways: ECHO Clinical TrialMedical experts evaluate unmet needs, key insights from the Phase 3 ECHO trial, and potential obstacles in integrating the findings into existing treatment protocols.
Latest:
Episode 3: Traversing the Complexities of Non-Clear Cell Renal Cell CarcinomaA brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.
Latest:
Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk StratificationThis study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.
Latest:
How to Treat Metastatic Malignant Triton Tumor in an AdolescentA systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
Latest:
Novel BTK Degrader Shows Activity in CLL/SLL Regardless of Mutation StatusCurrent findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Latest:
Best Practices for Referring Patients for CAR T TherapyPanelists discuss the growing importance of early integration and collaboration between community oncologists and specialized centers in the evolving chimeric antigen receptor (CAR) T-cell therapy landscape for multiple myeloma, emphasizing timely referrals, coordinated care, and strategic sequencing with other immunotherapies to optimize patient outcomes.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Alina Markova, MD, on the Future of Topical Ruxolitinib in Cutaneous Chronic GVHD and Multidisciplinary ImplicationsAlina Markova, MD, speaks about future research efforts for topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease, and multidisciplinary implications of current research.
Latest:
Implementing New Peritoneal Surface Malignancy Care Guidelines NationallyEpistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
Latest:
Fostering a Team-Based Approach to Elevate Neuro-Oncology CareSpecialties including neurosurgery, radiation oncology, and neurorehabilitation all play a notable role in the care of patients with brain tumors.
Latest:
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited SettingA recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting.
Latest:
Closing Thoughts, Future Perspectives, and Key Takeaways in the Treatment of Epithelioid SarcomaPanelists discuss how early recognition, accurate diagnosis through histopathology and molecular testing, and multidisciplinary collaboration are critical for optimizing treatment strategies in epithelioid sarcoma (ES), while future research into targeted therapies holds promise for improving outcomes, especially in advanced cases.
